Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Dow
Moodys
McKinsey
Harvard Business School

Last Updated: June 30, 2022

Tris Pharma Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Tris Pharma Inc
International Patents:19
US Patents:8
Tradenames:30
Ingredients:25
NDAs:29
Drug Master File Entries: 6
Patent Litigation for Tris Pharma Inc: See patent lawsuits for Tris Pharma Inc

Drugs and US Patents for Tris Pharma Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tris Pharma Inc DEXTROMETHORPHAN POLISTIREX dextromethorphan polistirex SUSPENSION, EXTENDED RELEASE;ORAL 091135-001 May 25, 2012 OTC No No See Plans and Pricing See Plans and Pricing
Tris Pharma Inc HYDROCODONE BITARTRATE AND ACETAMINOPHEN acetaminophen; hydrocodone bitartrate TABLET;ORAL 202214-006 Mar 15, 2016 AA RX No No See Plans and Pricing See Plans and Pricing
Tris Pharma Inc DEXMETHYLPHENIDATE HYDROCHLORIDE dexmethylphenidate hydrochloride TABLET;ORAL 207901-003 Aug 26, 2016 AB RX No No See Plans and Pricing See Plans and Pricing
Tris Pharma Inc DROXIDOPA droxidopa CAPSULE;ORAL 214543-003 May 5, 2021 AB RX No No See Plans and Pricing See Plans and Pricing
Tris Pharma Inc PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE codeine phosphate; promethazine hydrochloride SYRUP;ORAL 200386-001 Jun 29, 2012 AA RX No No See Plans and Pricing See Plans and Pricing
Tris Pharma Inc PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE dextromethorphan hydrobromide; promethazine hydrochloride SYRUP;ORAL 091687-001 Jun 28, 2012 AA RX No No See Plans and Pricing See Plans and Pricing
Tris Pharma Inc PROMETHAZINE HYDROCHLORIDE promethazine hydrochloride SYRUP;ORAL 091675-001 Jun 28, 2012 AA RX No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for Tris Pharma Inc Drugs

Country Patent Number Estimated Expiration
South Korea 101495146 See Plans and Pricing
China 101400343 See Plans and Pricing
Austria 536867 See Plans and Pricing
European Patent Office 2018160 See Plans and Pricing
Denmark 2018160 See Plans and Pricing
Russian Federation 2435569 See Plans and Pricing
Russian Federation 2008140944 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Tris Pharma Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1539166 122013000090 Germany See Plans and Pricing PRODUCT NAME: KOMBINATION AUS: (A) DEXTROMETHORPHAN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ, Z.B. DEXTROMETHORPHAN-HYDROBROMID UND INSBESONDERE DEXTROMETHORPHAN-HYDROBROMID-MONOHYDRAT; UND (B) CHINIDIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, Z.B.CHINIDIN-SULFAT UND INSBESONDERE CHINIDIN-SULFAT-DIHYDRAT; REGISTRATION NO/DATE: EU/1/13/833 20130624
0162036 C300028 Netherlands See Plans and Pricing PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
1441735 SPC/GB08/020 United Kingdom See Plans and Pricing PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102
1539166 92323 Luxembourg See Plans and Pricing PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
1539166 CR 2013 00059 Denmark See Plans and Pricing PRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
0196132 94C0008 Belgium See Plans and Pricing PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
1499331 13C0055 France See Plans and Pricing PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Mallinckrodt
McKesson
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.